# Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

> **NCT06193759** · PHASE1 · RECRUITING · sponsor: **Children's National Research Institute** · enrollment: 12 (estimated)

## Conditions studied

- Medulloblastoma, Childhood
- Atypical Teratoid/Rhabdoid Tumor of CNS
- Embryonal Tumor With Multilayered Rosettes
- Pineoblastoma
- Embryonal Brain Tumor Not Otherwise Specified
- Ependymoma

## Interventions

- **BIOLOGICAL:** Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)
- **DRUG:** Group A Standard-of-Care Backbone Therapy
- **RADIATION:** Group B Salvage Backbone Therapy

## Key facts

- **NCT ID:** NCT06193759
- **Lead sponsor:** Children's National Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2030-12-29
- **Final completion:** 2032-12-29
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06193759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06193759, "Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06193759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*